Dashboard
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 0.30%
- Poor long term growth as Net Sales has grown by an annual rate of -20.70% and Operating profit at 14.21% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- PRE-TAX PROFIT(Q) At CNY -10.26 MM has Fallen at -126.14%
- NET PROFIT(Q) At CNY -12 MM has Fallen at -133.15%
- NET SALES(Q) At CNY 86.34 MM has Fallen at -12.13%
2
With ROE of 303.13%, it has a fair valuation with a 105.21 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 4,709 Million (Mid Cap)
35.00
NA
0.00%
6.58
601.76%
126.25
Revenue and Profits:
Net Sales:
86 Million
(Quarterly Results - Sep 2025)
Net Profit:
-11 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-39.72%
0%
-39.72%
6 Months
-18.61%
0%
-18.61%
1 Year
20.25%
0%
20.25%
2 Years
104.68%
0%
104.68%
3 Years
51.26%
0%
51.26%
4 Years
10.07%
0%
10.07%
5 Years
26.25%
0%
26.25%
Hunan Jingfeng Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-20.70%
EBIT Growth (5y)
14.21%
EBIT to Interest (avg)
-1.61
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
5.50
Sales to Capital Employed (avg)
1.00
Tax Ratio
3.67%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.30%
ROE (avg)
44.62%
Valuation key factors
Factor
Value
P/E Ratio
35
Industry P/E
Price to Book Value
105.21
EV to EBIT
-173.38
EV to EBITDA
-961.16
EV to Capital Employed
12.35
EV to Sales
14.46
PEG Ratio
0.22
Dividend Yield
NA
ROCE (Latest)
-7.12%
ROE (Latest)
303.13%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
86.30
81.40
6.02%
Operating Profit (PBDIT) excl Other Income
0.30
-4.40
106.82%
Interest
0.00
7.80
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-11.10
-21.00
47.14%
Operating Profit Margin (Excl OI)
3.20%
-134.20%
13.74%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 6.02% vs -17.61% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 47.14% vs -87.50% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
412.40
650.50
-36.60%
Operating Profit (PBDIT) excl Other Income
11.10
-56.90
119.51%
Interest
40.40
42.00
-3.81%
Exceptional Items
238.80
-64.00
473.12%
Consolidate Net Profit
159.40
-227.50
170.07%
Operating Profit Margin (Excl OI)
-43.80%
-159.80%
11.60%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -36.60% vs -21.47% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 170.07% vs -138.72% in Dec 2023
About Hunan Jingfeng Pharmaceutical Co., Ltd. 
Hunan Jingfeng Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






